Second-Line Therapy for Metastatic TNBC

Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.

EP: 1.Background on Metastatic Triple Negative Breast Cancer

EP: 2.Initial Treatment Options for Metastatic TNBC

Now Viewing

EP: 3.Second-Line Therapy for Metastatic TNBC

EP: 4.ASCENT Study: Impact of Sacituzumab Govitecan on Metastatic TNBC

EP: 5.Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC

EP: 6.Overcoming Barriers to Treatment Access and Reimbursement

Related Videos